Why the study?
Does aspirin use reduce all-cause mortality and cardiovascular events in postmenopausal women with stable cardiovascular disease?
Population
8,928 postmenopausal women with stable cardiovascular disease enrolled in the Women's Health Initiative…
Comparison
Aspirin use (81 mg or 325 mg) vs No aspirin use
Design
Cohort
Follow-up
6.5 years
Authors
Loading...
Observational data should not change aspirin prescribing in postmenopausal women with stable CVD; leaves open whether RCTs would confirm mortality benefit.
Does aspirin use reduce all-cause mortality and cardiovascular events in postmenopausal women with stable cardiovascular disease?
In postmenopausal women with stable cardiovascular disease, aspirin use is associated with a significantly lower risk of all-cause and cardiovascular mortality, with no significant difference between 81 mg and 325 mg doses.
Berger et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: